18F-FDOPA PET imaging of brain tumors: Comparison study with 18F-FDG PET and evaluation of diagnostic accuracy

Journal of Nuclear Medicine

Volumn 47, Issue 6, 2006, Pages 904-911

  Chen, Wei ^a,b   Silverman, Daniel H S ^a   Delaloye, Sibylle ^a   Czernin, Johannes ^a   Kamdar, Nirav ^a   Pope, Whitney ^a   Satyamurthy, Nagichettiar ^a   Schiepers, Christiaan ^a   Cloughesy, Timothy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WOODLAND HILLS MEDICAL CENTER   (United States)

Author keywords

18F FDG; 18F FDOPA; Accuracy; Brain tumors; Diagnosis; PET

Indexed keywords

3,4 DIHYDROXY 6 FLUORO PHENYLALANINE F 18; DEXAMETHASONE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORODOPA F 18;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION NECROSIS; TREATMENT OUTCOME; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED CLINICAL TRIAL; IMAGE ENHANCEMENT; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STATISTICS; UNITED STATES;

ADULT; AGED; BRAIN NEOPLASMS; CALIFORNIA; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33746082501     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology. 1982;144:885-889.
2. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR. 1988;150:189-197.
3. 82Rb positron emission tomography. J Comput Assist Tomogr. 1987;11:563-570.
4. Wong TZ, van der Westhuizen GJ, Coleman RE. Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am. 2002;12:615-626.
5. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumors: Is it useful? J Neurol Neurosurg Psychiatry. 1995;58:250-252.
6. Ricci PE, Karis JP, Heisennan JE, et al. Differentiaing recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? Am J Neuroradiol. 1998;19:407-413.
7. Delbeke D, Meyerowitz C, Lapidus RL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47-52.
8. Padoma MV, Said S, Jacobs M, et al. Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol. 2003;64:227-237.
9. Ishiwata K, Kutota K, Murakami M, et al. Reevaluation of amino acid PET studies: Can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med. 1993;34:1936-1943.
10. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432-445.
11. 11C-Methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322.
12. Laverman P, Boerman OC, Corstens FHM, et al. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur J Nucl Med. 2002;29:681-690.
13. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40:205-212.
14. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
15. 18F] Fluoroelhyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain. 2005;128:678-687.
16. Heiss WD, Wienhard K, Wagner R, et al. F-Dopa as an amino acid tracer to detect brain tumors. J Nucl Med. 1996;37:1180-1182.
17. 11C]methionine. Eur J Nucl Med Mol Imaging. 2003;30:1561-1567.
18. Beuthien-Baumann B, Bredow J, Burchert W, et al. 3-O-Methyl-6- [18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging. 2003;30:1004-1008.
19. 18F]fluor-L-dopa. Appl Radiat Isot. 1992;43:989-996.
20. 18F]OF2. Nucl Med Biol. 1996;23:189-199.
21. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg. 1995;83:657-664.
22. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med. 1999;26:1501-1509.
23. Oldendorf WH, Szabo J. Amino acid assignment to one of the three blood-brain barrier amino acid carriers. Am J Physiol. 1976;230:94-98.
24. Garnett S, Firnau G, Nahmias C, Chirakal R. Striatal dopamine metabolism in living monkeys examined by positron emission tomography. Brain Res. 1983;280:169-171.
25. Garnett ES, Fimau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature. 1983;305:137-138.
26. Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004;6:239-269.
27. 18F]fluoro-L-DOPA. Biochem Pharmacol. 2001;62:1409-1415.
28. Stout DB, Huang SC, Melega WP, et al. Effects of large neutral amino acid concentrations on 6-[F-18]fluoro-L-DOPA kinetics. J Cereb Blood Flow Metab. 1998;18:43-51.
29. 11C]-L-methionine uptake in cerebral gliomas: a comparative study using SPECT and PET. J Nucl Med. 1997;38:517-522.
30. 11C]-L-methionine transport into the human brain. J Cereb Blood Flow Metab. 1988;8:341-345.
31. Langen KJ, Clauss RP, Holschbach M, et al. Comparison of iodotyrosines and methionine uptake in a rat glioma model. J Nucl Med. 1998;39:1596-1599.
32. Langen KJ, Jarosch M, Muhlensiepen H, et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol. 2003;30:501-508.
33. 18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro. J Nucl Med. 2004;45:2116-2122.